Bio-Rad Laboratories, Inc.
BIO
$265.26
$0.940.36%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 651.60M | 585.40M | 667.48M | 649.73M | 638.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 651.60M | 585.40M | 667.48M | 649.73M | 638.50M |
| Cost of Revenue | 306.20M | 274.80M | 325.56M | 293.83M | 282.80M |
| Gross Profit | 345.40M | 310.60M | 341.91M | 355.90M | 355.70M |
| SG&A Expenses | 205.20M | 193.50M | 204.36M | 200.34M | 196.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 572.20M | 528.50M | 609.55M | 585.16M | 538.80M |
| Operating Income | 79.40M | 56.90M | 57.93M | 64.57M | 99.70M |
| Income Before Tax | 414.00M | 83.40M | -908.92M | 861.62M | -2.79B |
| Income Tax Expenses | 96.20M | 19.40M | -193.12M | 208.45M | -620.80M |
| Earnings from Continuing Operations | 317.80M | 64.00M | -715.80M | 653.17M | -2.17B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 317.80M | 64.00M | -715.80M | 653.17M | -2.17B |
| EBIT | 79.40M | 56.90M | 57.93M | 64.57M | 99.70M |
| EBITDA | 120.00M | 95.00M | 97.13M | 103.47M | 136.10M |
| EPS Basic | 11.67 | 2.29 | -25.57 | 23.37 | -76.26 |
| Normalized Basic EPS | 1.86 | 1.89 | 1.40 | 1.49 | 2.37 |
| EPS Diluted | 11.67 | 2.29 | -25.57 | 23.34 | -76.26 |
| Normalized Diluted EPS | 1.86 | 1.88 | 1.40 | 1.49 | 2.37 |
| Average Basic Shares Outstanding | 27.23M | 27.94M | 28.00M | 27.95M | 28.40M |
| Average Diluted Shares Outstanding | 27.23M | 27.96M | 28.00M | 27.99M | 28.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |